The AI drug revolution is real but the hype around it isn’t

If you listen to the brightest minds in tech right now, you might think human disease is just a software bug waiting for a patch. ​At the 2025 World Economic Forum in Davos, Anthropic CEO Dario Amodei—drawing on his background in biophysics—predicted that AI could condense a century of biological progress into a single decade, potentially doubling human lifespans. Demis Hassabis, the Nobel laureate behind Google DeepMind, recently floated a similarly audacious timeline, suggesting that AI could help eliminate all diseases within 10 years. Hassabis aims to shrink the decade-long drug design process down to mere months. ​I’ve spent my career straddling the mathematical elegance of artificial intelligence and the grueling, messy reality of drug discovery. So, when I hear these predictions, I get it. Silicon Valley loves a moonshot. But some of the rhetoric implies that one day we might treat the human body like software—diagnosing problems, simulating fixes, and “debugging” disease before